Auro Vaccines LLC products

The Auro Vaccines discovery engine is rapidly creating a pipeline of differentiated new vaccines. On the leading edge of development are:

Auro Vaccines has developed VesiculoVax™-vectored vaccines for pre- and post-exposure protection against the hemorrhagic disease caused by multiple species of filovirus (i.e. Zaire ebolavirus, Sudan ebolavirus and Marburg virus).

Auro Vaccines has developed a VesiculoVax™-vectored vaccine to protect against the arthralgic disease caused by infection with Chikungunya virus.

Auro Vaccines has developed a VesiculoVax™-vectored vaccine to protect against Lassa hemorrhagic fever.

Auro Vaccines is developing a GeneVax prime/VesiculoVax boost therapeutic HPV vaccine for use as an adjunct to surgery that targets the seven HPV types responsible for more than 92% of cervical and head and neck cancers.

Auro Vaccines has also developed a GeneVax prime/VesiculoVax boost therapeutic vaccine that targets all eight HBV genotypes for use as an adjunct to drug therapy.

Auro Vaccines is developing a GeneVav prime/VesiculoVax™ boost therapeutic vaccine that targets all HCV genotypes for use as an adjunct to drug therapy.

Auro Vaccines is developing a GeneVax prime/VesiculoVax boost therapeutic vaccine for herpes simplex virus type-2. This vaccine is designed to ameliorate disease and transmission by preventing HSV-2 reactivation and shedding.

As part of its comprehensive Public Health and Biodefense vaccine franchise, under a license from the Henry M. Jackson Foundation, Auro Vaccines is developing a subunit vaccine (HeV-sG-V) composed of the envelope glycoprotein of Hendra virus for the prevention of Nipah virus (NiV) infection.